Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL
Open Access
- 20 January 2005
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (3) , 325-334
- https://doi.org/10.1111/j.1365-2125.2004.02325.x
Abstract
Aim The vehicle Cremophor EL (CrEL) has been shown to impair the absorption of paclitaxel by micellar entrapment of the drug in the gastrointestinal tract. The goal of this study was to develop a semimechanistic population pharmacokinetic model to study the influence of CrEL on the oral absorption of paclitaxel. Method Paclitaxel plasma‐concentration time profiles were available from 55 patients (M:F, 17 : 38; total 67 courses; 797 samples), receiving paclitaxel orally once or twice daily (dose range 60–360 mg m−2) together with 12–15 mg kg−1 cyclosporin A. A population pharmacokinetic model was developed using the nonlinear mixed effect modelling program NONMEM. Results After absorption, paclitaxel pharmacokinetics were best described using a two‐compartment model with linear distribution from the central compartment into a peripheral compartment and first‐order elimination. Paclitaxel in the gastrointestinal tract was modelled as free fraction or bound to CrEL, with only the free fraction available for absorption into the central compartment. The equilibrium between free and bound paclitaxel was influenced by the concentration of CrEL present in the gastrointestinal tract. The concentration of CrEL in the gastrointestinal tract decreased with time with a first order rate constant of 1.73 h−1. The bioavailability of paclitaxel was independent of the dose and of CrEL. Estimated apparent paclitaxel clearance and volume of distribution were 127 l h−1 and 409 l, respectively. Large interpatient variability was observed. Covariate analysis did not reveal significant relationships with any of the pharmacokinetic parameters. Conclusion A pharmacokinetic model was developed that described the pharmacokinetics of orally administered paclitaxel. CrEL strongly influenced paclitaxel absorption from the gastrointestinal tract resulting in time‐dependent but no significant dose‐dependent absorption over the examined dose range studied.Keywords
This publication has 40 references indexed in Scilit:
- Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- Review : Cremophor: Pharmacological activity of an "inert" solubiliserJournal of Oncology Pharmacy Practice, 1997
- Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human fecesCancer Chemotherapy and Pharmacology, 1995
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6?-hydroxytaxolCancer Chemotherapy and Pharmacology, 1995
- Taxanes: A New Class of Antitumor AgentsCancer Investigation, 1995
- Isolation, Structural Determination, and Biological Activity of 6.alpha.-Hydroxytaxol, the Principal Human Metabolite of TaxolJournal of Medicinal Chemistry, 1994
- Effect of misspecification of the absorption process on subsequent parameter estimation in population analysisJournal of Pharmacokinetics and Biopharmaceutics, 1993